arrow
R

Romain Altwegg

hopital universitaire henri-mondor - aphp
H指数:34
被引数:4,227

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Acceptability and tolerability of risankizumab maintenance therapy administered via on-body injector in patients with Crohn’s disease: Results of the ACCEPT-OBI study

克罗恩病患者通过自体注射器接受 risankizumab 维持治疗的接受度和耐受性:ACCEPT-OBI 研究结果

2026-09-100
PRE
Association of bowel urgency, disease activity and disability in patients with inflammatory bowel disease: A cross-sectional study from the GETAID

炎症性肠病患者肠道急迫感、疾病活动度与残疾的相关性:一项来自GETAID的横断面研究

2026-08-010
PRE
Real world experience with granulocyte and monocyte adsorptive apheresis (ADACOLUMN®) in patients with refractory inflammatory bowel disease: a retrospective observational multicenter cohort study

粒细胞和单核细胞吸附性单采(ADACOLUMN®)在难治性炎症性肠病患者中的真实世界经验:一项回顾性多中心队列研究

2026-07-010
PRE
Subcutaneous vedolizumab dose intensification in inflammatory bowel disease patients: the OPTI-VEDO multicenter study from the GETAID

皮下注射维多利珠单抗剂量强化在炎症性肠病患者中的应用:GETAID组织的OPTI-VEDO多中心研究

2025-09-010
PRE
Comparative effectiveness of tofacitinib versus upadacitinib for the treatment of acute severe ulcerative colitis

托法替布与乌帕替尼治疗急性重度溃疡性结肠炎的疗效比较

2025-07-260
OAAI
A randomized controlled trial of antibiotics targeting adherent and invasive Escherichia coli versus placebo in Crohn's disease: the TEOREM trial

针对黏附侵袭性大肠杆菌的抗生素与安慰剂在克罗恩病中的随机对照试验:TEOREM试验。J. Crohns Colitis 19, jjaf093

2025-07-012
PRE
PErsistence and Safety of Subcutaneous Infliximab 1 Year After Switch From Intravenous Route in IBD Patients in REMission

IBD缓解期患者从静脉给药途径转换为皮下给药途径1年后英夫利昔单抗的持续疗效与安全性

2025-05-190
PRE
Effectiveness and Safety of Upadacitinib Induction Therapy for 223 Patients With Crohn's Disease: A GETAID Multicentre Cohort Study

乌帕替尼诱导治疗223例克罗恩病患者的有效性与安全性:一项GETAID多中心队列研究

2025-03-042
OAAI
Effectiveness and Safety of Upadacitinib Induction Therapy in Real-World Setting for 234 Patients with Crohn's Disease: A GETAID Multicentre Cohort Study
2025-01-220
PRE
Dose intensification of subcutaneous vedolizumab is an effective and safe option in Inflammatory Bowel Disease patients: Results from the multicentre OPTI-VEDO study
2025-01-220
PRE
Comparative efficacy of infliximab and vedolizumab after failure of a first anti-TNF in patients with ulcerative colitis: a double-blind randomized controlled trial (EFFICACI)
2025-01-220
PRE